Items Tagged ‘TH3RESA trial’

January 6th, 2016

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer

By

Patients with metastatic, HER2-positive breast cancer who received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute reported the findings at the 2015 San Antonio Breast Cancer Symposium. The TH3RESA trial, which enrolled more than 600 participants in the U.S. […]

View full entry

Tags: antibody, Breast Cancer, Chemotherapy, combination therapy, HER2-positive, meastatic breast cancer, Metastatic Breast Cancer, News, T-DMI, TH3RESA trial, trastuzumab emtansine


January 3rd, 2016

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer

By

Patients with metastatic, HER2-positive breast cancer received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute reported the findings at the 2015 San Antonio Breast Cancer Symposium. The TH3RESA trial, which enrolled more than 600 participants in the U.S. and […]

View full entry

Tags: Breast Cancer, HER2-positive, metastatic, Metastatic Breast Cancer, News, Stages II-III Breast Cancer, T-DMI, TH3RESA trial, trastuzumab emtansine